BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 21190999)

  • 21. A687V EZH2 is a gain-of-function mutation found in lymphoma patients.
    Majer CR; Jin L; Scott MP; Knutson SK; Kuntz KW; Keilhack H; Smith JJ; Moyer MP; Richon VM; Copeland RA; Wigle TJ
    FEBS Lett; 2012 Sep; 586(19):3448-51. PubMed ID: 22850114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone H3 tail binds a unique sensing pocket in EZH2 to activate the PRC2 methyltransferase.
    Jani KS; Jain SU; Ge EJ; Diehl KL; Lundgren SM; Müller MM; Lewis PW; Muir TW
    Proc Natl Acad Sci U S A; 2019 Apr; 116(17):8295-8300. PubMed ID: 30967505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reaction coupling between wild-type and disease-associated mutant EZH2.
    Swalm BM; Knutson SK; Warholic NM; Jin L; Kuntz KW; Keilhack H; Smith JJ; Pollock RM; Moyer MP; Scott MP; Copeland RA; Wigle TJ
    ACS Chem Biol; 2014 Nov; 9(11):2459-64. PubMed ID: 25154026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
    Wu D; Zeng X; Zhao Y; Qin M; Gong P
    Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
    Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
    ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of histone methylation by automethylation of PRC2.
    Wang X; Long Y; Paucek RD; Gooding AR; Lee T; Burdorf RM; Cech TR
    Genes Dev; 2019 Oct; 33(19-20):1416-1427. PubMed ID: 31488576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.
    Lee CH; Holder M; Grau D; Saldaña-Meyer R; Yu JR; Ganai RA; Zhang J; Wang M; LeRoy G; Dobenecker MW; Reinberg D; Armache KJ
    Mol Cell; 2018 May; 70(3):435-448.e5. PubMed ID: 29681498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
    Xu B; Konze KD; Jin J; Wang GG
    Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
    Gibaja V; Shen F; Harari J; Korn J; Ruddy D; Saenz-Vash V; Zhai H; Rejtar T; Paris CG; Yu Z; Lira M; King D; Qi W; Keen N; Hassan AQ; Chan HM
    Oncogene; 2016 Feb; 35(5):558-66. PubMed ID: 25893294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
    Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
    Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
    Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
    Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
    Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
    Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2.
    Friedman J; Cho WK; Chu CK; Keedy KS; Archin NM; Margolis DM; Karn J
    J Virol; 2011 Sep; 85(17):9078-89. PubMed ID: 21715480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.
    Mochizuki-Kashio M; Mishima Y; Miyagi S; Negishi M; Saraya A; Konuma T; Shinga J; Koseki H; Iwama A
    Blood; 2011 Dec; 118(25):6553-61. PubMed ID: 22042701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
    Souroullas GP; Jeck WR; Parker JS; Simon JM; Liu JY; Paulk J; Xiong J; Clark KS; Fedoriw Y; Qi J; Burd CE; Bradner JE; Sharpless NE
    Nat Med; 2016 Jun; 22(6):632-40. PubMed ID: 27135738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.
    Simon C; Chagraoui J; Krosl J; Gendron P; Wilhelm B; Lemieux S; Boucher G; Chagnon P; Drouin S; Lambert R; Rondeau C; Bilodeau A; Lavallée S; Sauvageau M; Hébert J; Sauvageau G
    Genes Dev; 2012 Apr; 26(7):651-6. PubMed ID: 22431509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substrate preferences of the EZH2 histone methyltransferase complex.
    Martin C; Cao R; Zhang Y
    J Biol Chem; 2006 Mar; 281(13):8365-70. PubMed ID: 16431907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mutation in the E(Z) methyltransferase that increases trimethylation of histone H3 lysine 27 and causes inappropriate silencing of active Polycomb target genes.
    Stepanik VA; Harte PJ
    Dev Biol; 2012 Apr; 364(2):249-58. PubMed ID: 22182520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.